Can the ex-Aragon team pull off a repeat with another new drug for mCRPC

According to an article by Alex Lash on the Xconomy web site, a start-up biotech company in South San Francisco called ORIC Pharmaceuticals will — at least initially — be highly focused on new drug therapies for men with very late-stage prostate cancer.

Normally we don’t bother to mention such start-ups until they have really meaningful data that imply the potential for approval of effective and safe therapies. In this case, however, the business team includes many of the same people whose work led to the development of ARN-509 at Aragon Pharmaceuticals (later sold to Johnson & Johnson and now in Phase III clinical trials). This is clearly a team with a track record, and once again they have enlisted the cooperation of Dr. Charles Sawyers and his research laboratory at Memorial Sloan-Kettering Cancer Center. The initial product is based on a protein on the prostate cancer tumor surface called the glucocorticoid (GC) receptor, and ORIC plans to develop this as a treatment for men with metastatic, castration-resistant prostate cancer who are also resistant to treatment with enzalutamide (Xtandi)

This is clearly a company that the advanced prostate cancer community will want to be keeping an eye on for a while.

One Response

  1. Sawyers played a pivotal role in developing Gleevec, as well. I agree with you that this means business.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: